TGF-β1/TRAF-6 and IL-6/STAT-3 pathways in PSA-PSMA phenotypes of hormone-sensitive and hormone-refractory prostate Cancer
Clinical Immunology · 2026-04 · 284 · 110679
DOI: 10.1016/j.clim.2026.110679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2026-04. Verfasst von Awatef Ben Jemaa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit IMEC-Immunology Microbiology Environmental and Carcinogenesis, Faculty of Science of Bizerte, University of Carthage, Tunisia; Department of Bio…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Interleukin-6, Transforming Growth Factor beta1, Prostatic Neoplasms. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Républic Tunisienne Ministère de l'Enseignement Supérieur et de la Recherche Scientifique.
Abstract (Originalsprache)
This study explored the relationship between systemic cytokines and PSA-PSMA phenotypes in benign prostatic hyperplasia (BPH) and prostate cancer (PCa), including hormonal therapy response. Serum cytokines (IL-6, TNF-α, IL-10, IL-17 A, TGF-β1) and PSA were quantified, while tissue PSA, PSMA, CD34, TRAF-6, and phosphorylated STAT3 (Ser727, Tyr705) were evaluated immunohistochemically. AR and AR-V7 mRNA expression were assessed by RT-PCR. PCa patients exhibited elevated IL-6 and TGF-β1, higher PSMA and CD34, and reduced tissue PSA compared to BPH. pSTAT3 (Tyr705) increased, whereas pSTAT3 (Ser727) decreased in PCa. In hormone-refractory PCa, TGF-β1 and PSMA were elevated, while PSA declined. AR-V7 was largely absent, and TRAF-6 showed no hormonal difference. These findings suggest IL-6/STAT3 and TGF-β1/TRAF-6 pathways modulate PSA-PSMA dynamics, with TGF-β1/TRAF-6 particularly linked to hormone-refractory progression. Cytokine-mediated signaling may inform PCa diagnosis, prognosis, and therapeutic targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit IMEC-Immunology Microbiology Environmental and Carcinogenesis, Faculty of Science of Bizerte, University of Carthage, Tunisia; Department of Biology, Faculty of Science of Gafsa, University of Gafsa, Tunisia. Elect…
- Department of Immunology, Military Hospital of Tunis, 1008 Montfleury, Tunis, Tunisia.
- Department of Urology, La Rabta Hospital, University Tunis Al Manar, Tunis, Tunisia.
- Unit IMEC-Immunology Microbiology Environmental and Carcinogenesis, Faculty of Science of Bizerte, University of Carthage, Tunisia.
Förderung
- Républic Tunisienne Ministère de l'Enseignement Supérieur et de la Recherche Scientifique
Zitieren
APA
Jemaa, A. B., Azaiez, M. B., Sallami, S., Nouira, Y., Ghazouani, E., & Oueslati, R. (2026). TGF-β1/TRAF-6 and IL-6/STAT-3 pathways in PSA-PSMA phenotypes of hormone-sensitive and hormone-refractory prostate Cancer. Clinical Immunology, 284, 110679. https://doi.org/10.1016/j.clim.2026.110679
Vancouver
Jemaa AB, Azaiez MB, Sallami S, Nouira Y, Ghazouani E, Oueslati R. TGF-β1/TRAF-6 and IL-6/STAT-3 pathways in PSA-PSMA phenotypes of hormone-sensitive and hormone-refractory prostate Cancer. Clinical Immunology. 2026;284:110679. doi:10.1016/j.clim.2026.110679
BibTeX
@article{Jemaa2026,
author = {Jemaa, Awatef Ben and Azaiez, Mouna Ben and Sallami, Sataa and Nouira, Yassine and Ghazouani, Ezzeddine and Oueslati, Ridha},
title = {TGF-β1/TRAF-6 and IL-6/STAT-3 pathways in PSA-PSMA phenotypes of hormone-sensitive and hormone-refractory prostate Cancer},
journal = {Clinical Immunology},
year = {2026},
volume = {284},
pages = {110679},
doi = {10.1016/j.clim.2026.110679}
}
EUVIMED